CMG Pharmaceutical Co. Ltd
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic colla… Read more
CMG Pharmaceutical Co. Ltd (058820) - Total Liabilities
Latest total liabilities as of September 2025: ₩103.30 Billion KRW
Based on the latest financial reports, CMG Pharmaceutical Co. Ltd (058820) has total liabilities worth ₩103.30 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CMG Pharmaceutical Co. Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how CMG Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CMG Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of CMG Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sichuan Langsha Holding Ltd
SHG:600137
|
China | CN¥139.62 Million |
|
Caswell Inc
TW:6416
|
Taiwan | NT$1.92 Billion |
|
Tethys Oil AB
ST:TETY
|
Sweden | Skr41.50 Million |
|
Audix Corp
TW:2459
|
Taiwan | NT$3.14 Billion |
|
Guan Chong Bhd
KLSE:5102
|
Malaysia | RM5.99 Billion |
|
Frontera Energy Corp
PINK:FECCF
|
USA | $1.20 Billion |
|
i-SENS Inc
KQ:099190
|
Korea | ₩238.13 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down CMG Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CMG Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CMG Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual total liabilities of CMG Pharmaceutical Co. Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩113.89 Billion | +119.60% |
| 2023-12-31 | ₩51.87 Billion | +83.22% |
| 2022-12-31 | ₩28.31 Billion | +95.60% |
| 2021-12-31 | ₩14.47 Billion | +1.74% |
| 2020-12-31 | ₩14.22 Billion | +17.71% |
| 2019-12-31 | ₩12.08 Billion | +16.22% |
| 2018-12-31 | ₩10.40 Billion | -10.55% |
| 2017-12-31 | ₩11.62 Billion | +17.75% |
| 2016-12-31 | ₩9.87 Billion | +1.50% |
| 2015-12-31 | ₩9.73 Billion | +7.28% |
| 2014-12-31 | ₩9.07 Billion | +31.10% |
| 2013-12-31 | ₩6.92 Billion | -72.90% |
| 2012-12-31 | ₩25.52 Billion | +175.24% |
| 2011-12-31 | ₩9.27 Billion | -- |